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Abstract
Introduction: Nerve growth factor plays a key role in the pathology of osteoarthritis (OA) related chronic pain. The
aim of these studies was to evaluate the safety, tolerability, pharmacokinetics, and clinical response of AMG 403, a
human anti-nerve growth factor monoclonal antibody, in healthy volunteers and subjects with knee OA.
Methods: Two phase I, randomized, placebo-controlled, double-blind studies were conducted. The single-ascending
dose study randomized healthy volunteers (n = 48) 3:1 to receive AMG 403 (1, 3, 10, or 30 mg intravenously; or 10 or 30
mg subcutaneously; n = 8 per group) or placebo. The multiple-ascending dose study randomized knee OA subjects
(n = 18) 3:1 to receive AMG 403 (3, 10, or 20 mg subcutaneously once monthly for four doses) or placebo. Safety,
tolerability, and pharmacokinetics (PK) were assessed for both studies. Patient’s and physician’s disease assessments and
total WOMAC score were determined in knee OA subjects.
Results: AMG 403 appeared to be well-tolerated after single and multiple doses, except for subject-reported
hyperesthesia, pain, and paresthesia (mild to moderate severity). These treatment-emergent neurosensory events
showed evidence of reversibility and a possible dose-dependence. Three serious adverse events were reported in
AMG 403 treated subjects, but were not considered treatment related. AMG 403 PK was linear with an estimated
half-life of 19.6 to 25.8 days. After multiple doses, AMG 403 PK showed modest accumulation (≤2.4-fold increase)
in systemic exposure. Knee OA diagnosis, body weight, and anti-drug antibody development did not appear to
affect AMG 403 PK. Patient’s and physician’s disease assessments and total WOMAC score showed improvement
in AMG 403 treated knee OA subjects compared with placebo.
Conclusions: AMG 403 was generally safe and well-tolerated in both healthy volunteers and knee OA patients,
and exhibited linear pharmacokinetics. Preliminary clinical efficacy was observed in knee OA subjects.
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Introduction
Osteoarthritis (OA) is a painful and disabling inflamma-
tory disease of the joints and is the most prevalent form of
arthritis, affecting more than 26 million US adults [1–3].
It is caused by multiple factors (e.g., joint injury or over-
use, obesity, and heredity) and dramatically increases in
prevalence with age [1]. The disease pathology involves
breakdown of joint cartilage, tendon and ligament stretch,
and when severe, bone erosion [4]. OA can affect the
hands and weight-bearing joints, such as knees, hips,
feet, and lower back [5]. Joint stiffness, pain, and loss of
joint movement are typical symptomatic manifestations
that are used to assess disease severity based on various
metrics, such as the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) [6, 7].
Pain is the principal reason why OA patients seek
medical care and it is a major determinant of other OA
disease outcomes such as disability and joint replacement
[8, 9]. Chronic use of commonly prescribed therapies for
OA pain, such as nonsteroidal anti-inflammatory drugs
(NSAIDs) and opioids, is often hindered by safety issues
and the development of tolerance [10]. While the etiology
of OA pain is unclear, the investigation of novel pain
pathways is necessary to provide improved treatment
over the typical therapies, many of which were ap-
proved decades ago.
Nerve growth factor (NGF) contributes to persistent
pain in a variety of animal models and is elevated in
damaged peripheral tissues, and recent reviews thoroughly
present the rationale for targeting NGF in treating OA
pain [11, 12]. A member of the neurotrophin family, NGF
is a secreted, soluble protein that binds two different cell
surface receptors: the 75 kDa neurotrophin receptor
(p75NTR) which binds all neurotrophins with comparable
affinity, and the high-affinity NGF-specific tyrosine kinase
receptor (TrkA) that shows selectivity for NGF over other
neurotrophins [13]. Certain genetic variants of NGF or
TrkA are linked to decreased nociception or congenital
insensitivity, and elevated NGF levels are associated with
many chronic pain conditions [14, 15]. Preclinical use of
anti-NGF antibodies has demonstrated efficacy in rodent
models of inflammatory and neuropathic pain [16]. Fur-
thermore, sequestration of NGF via an anti-NGF antibody
has shown promising pain relief for OA patients in clinical
trials [17–19].
AMG 403 is a fully human immunoglobulin G2
(IgG2) monoclonal antibody that selectively binds
NGF. It is anticipated that AMG 403 will provide a
new treatment option for chronic OA pain, without
causing sedation or dependence. AMG 403, also
known as fulranumab, is currently in clinical develop-
ment. We report here the safety, tolerability, pharma-
cokinetics (PK), and clinical effect of AMG 403 observed
in two randomized, double-blind, placebo-controlled
phase I studies in healthy volunteers and patients
with knee OA.
Methods
The protocol and informed consent documentation for
the two phase I clinical studies were reviewed and
approved by the independent ethics committee or
institutional review board specific for the study center
and are listed in Additional file 1. The studies were
conducted in accordance with the International Confer-
ence on Harmonisation and Good Clinical Practice regu-
lations and guidelines. Written informed consent was
obtained from all study participants before any screening
or study-related procedures were performed.
Single-ascending dose study in healthy volunteers
This was a randomized, double-blind, placebo-controlled,
sequential, single-ascending dose study conducted from 18
January 2005 through 12 January 2006 at a single study
site. Inclusion criteria for enrollment followed the standard
practice for first-in-human studies. Briefly, eligible healthy
male and female volunteers were studied, who were of
non-child bearing potential between 18 and 55 years of age
(inclusive), with a body mass index (BMI) of 18 to
29 kg/m2. Clinical laboratory measurements and 12-lead
electrocardiogram intervals were assessed for general health
during the 21-day screening period. The day before dosing,
subjects were randomized to a single dose of AMG 403 or
placebo in a 3:1 ratio for each dose regimen. The double-
blind treatment/follow-up period was either 49 (1 and 3 mg
AMG 403) or 91 (10 and 30 mg AMG 403) days in
duration. Single doses of AMG 403 were administered by
either one-hour intravenous (IV) infusion (1, 3, 10,
and 30 mg) or subcutaneous (SC) injection (10 and 30 mg).
Multiple-ascending dose study in patients with knee OA
This was a randomized, double-blind, placebo-controlled,
sequential, multiple-dose study conducted at three sites
from 13 December 2006 through 17 January 2008. Eligible
male and female subjects 18 to 65 years of age (inclusive),
body weight <125 kg, and diagnosed with knee OA (as de-
fined by the following American College of Rheumatology
criteria: knee pain and radiographic evidence of osteo-
phytes, and morning stiffness for ≤30 minutes and/or
crepitus on motion) were enrolled. At screening, subjects
were to have visual analog scale (VAS) pain scores ≥30
mm for the index knee and clinically acceptable laboratory
tests and electrocardiogram results. If patients were taking
any non-prescribed supplements or prescription medica-
tions including pain medication, the doses were to have
been stable for at least 1 month.
Key exclusion criteria included active or prior history of
peripheral neuropathy, paresthesia, or dysesthesia or any
other previously diagnosed neurologic condition causing
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the above noted symptoms; uncontrolled diabetes, cardio-
vascular disease or hypertension; diagnosis of a condition
other than knee OA that could cause or affect pain or pain
assessment in the index knee (e.g., radiculopathy or neur-
opathy, vasculopathy, fibromyalgia or active depression);
neuromodulatory agents used as analgesic therapy for
neuropathic pain; planned surgical treatment for OA dur-
ing the study period; inflammatory arthropathy including
secondary OA; smoking more than 20 cigarettes per day
within the 12 months prior to first dose administration;
women of child-bearing potential; current or recent use of
opiates or Diacerein (≤1 week prior to first AMG 403 dose
administration).
The study design consisted of a 21-day screening, 112-
day double-blind efficacy, and 126-day post-treatment
follow-up period. In each dose cohort (3, 10, or 20 mg
AMG 403), subjects were randomized 3:1 to receive
AMG 403 or placebo, once every 4 weeks (Q4W) by SC
injection for a total of four dose administrations. Admin-
istration of the second, third, and fourth doses occurred
only after the previous dose was found to be safe and
well-tolerated based on protocol-specified stopping
rules. Dose escalation to the next dose cohort proceeded
only when the previous dose cohort was found to be safe
and well-tolerated following a review of all available
safety data to day 22.
Safety
Safety assessments included vital signs, laboratory tests,
12-lead electrocardiogram, and neurological and injection
site evaluations for the determination of adverse events
(AE) and serious adverse events (SAE) from study enroll-
ment to end of study.
Immunogenicity
Serum samples were collected from healthy volunteers
(single-dose study) on study days 1 (pre-dose), 29, 50
(only 1, 3, and 10 mg IV), or day 92 (only 10 and 30 mg
IV, and 10 and 30 mg SC), and from patients with knee
OA (multiple-dose study) on study days 1 (pre-dose), 29
(pre-dose), 57 (pre-dose), 85 (pre-dose), 197 (only 3 and
10 mg SC Q4W), or 211 (20 mg SC Q4W). All samples
were first tested for anti-drug antibodies (ADA) using a
validated electrochemiluminescent (ECL) immunoassay
to screen and confirm antibodies capable of binding
AMG 403. Samples testing positive in the ECL immuno-
assay were subsequently tested in a validated cell-based
bioassay to detect AMG 403 neutralizing or inhibitory
effects in vitro. Samples that tested negative in the ECL
immunoassay were not tested in the bioassay. Subjects
were designated with a positive immune response if anti-
bodies to AMG 403 were detected at any time point
subsequent to the first dose administration.
Pharmacokinetics
Serum samples were collected from subjects while on
study at protocol-specific time points. Serum AMG 403
levels were measured using validated enzyme-linked im-
munosorbent assays with a lower limit of quantification
(LLOQ) of 0.0016 or 0.0051 μg/mL for the single- and
multiple-dose studies, respectively. PK parameters were
derived from non-compartmental analysis using Phoenix
WinNonlin 6.3 (Pharsight, Mountain View, CA, USA).
Population PK modeling with covariate analysis
From model development a two-compartment model was
identified as the appropriate choice for a combined ana-
lysis of the individual PK data from healthy volunteers and
patients with knee OA, using NONMEM 7.2 (ICON
Development Solutions, Ellicott City, MD, USA). The fol-
lowing population PK (pop PK) parameters were esti-
mated: first-order SC absorption rate (ka), clearance (CL),
central volume of distribution (Vc), peripheral volume of
distribution (Vp), intercompartmental CL (Q), and bio-
availability (F) of a SC dose. Baseline body weight was
evaluated as a continuous covariate on CL and Vc. Knee
OA diagnosis and ADA development to AMG 403 were
independently tested as dichotomous covariates on CL.
Efficacy in patients with knee OA
A 100-mm VAS was used for patients’ self-assessment of
knee OA as “very good” to “very poor” [20]. Physician dis-
ease assessment rated the condition of the study subject’s
knee on a scale of 0 to 4 (0 = very good and 4 = very poor).
Study subjects independently reported answers to the
Western Ontario and McMaster Universities Osteoarth-
ritis Index (WOMAC) 3.1 questionnaire to measure the
three components of OA symptoms: pain, stiffness, and
physical function. Baseline determinations for all three
efficacy endpoints were assessed prior to the first dose ad-
ministration and at various time points during treatment.
Statistical analysis
All subjects who received at least one dose of AMG 403
were included in the safety and efficacy analyses. Adverse
events, PK, and efficacy endpoints were descriptively com-
pared across the various treatment groups, as the study
was not powered to perform formal statistical testing.
Results
Study subject characteristics
Of the 46 healthy volunteer subjects enrolled in the
single-dose study, 34 received AMG 403 and 12 received
matching placebo. In the multiple-dose knee OA study, 18
subjects received AMG 403 and six subjects received
matching placebo (Table 1). Mean age and weight were
typically higher for patients with knee OA than for healthy
volunteer subjects. For both studies combined, all subjects
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were Caucasian, except for three African-Americans in
the multiple-dose study (one each in the placebo, 10-mg,
and 20-mg SC Q4W groups), and most subjects were
male (77 %). Disease activity at screening in patients with
knee OA in the multiple-dose study was generally similar
across the cohorts.
Safety
In the single-dose study with healthy volunteers, no sub-
jects were removed from the study due to AEs and there
were no deaths during the study. Only one SAE was re-
ported (pneumothorax, 10 mg IV AMG 403), but it was
not considered to be treatment-related (Table 2).
Treatment-emergent adverse events (TEAEs) related to
sensory symptomatology reported by 5 % or more of all
subjects who received AMG 403 were headache (6/34
subjects, 18 %), pain in an extremity (4/34, 12 %), and
hyperesthesia (3/34, 9 %). Furthermore, pain in the
extremities and hyperesthesia were only reported at the
highest dose level (30 mg IV and SC). TEAEs reported by
5 % or more of all healthy volunteers who received AMG
403 were herpes simplex (5/34 subjects, 15 %) and dizzi-
ness (3/34, 9 %). Herpes simplex/oral herpes were
reported by one of 12 (8 %) placebo subjects and by one
subject in each of the AMG 403 treatment groups, except
10 mg SC. The clinical significance and relationship of the
reported cold sores to AMG 403 were unclear. Only one
AMG 403-treated subject experienced an injection-site
reaction (mild transient pruritus, 30 mg SC).
In the multiple-dose study with patients with knee OA,
AMG 403 appeared to be generally well-tolerated (Table 2)
except for sensory symptomatology TEAEs: arthralgia
(4/18 subjects, 22 %), headache (4/18, 22 %), paresthesia
(3/18, 17 %), and myalgia (2/18, 11 %). Paresthesia TEAEs
were only in the highest multiple-dose group (20 mg SC
Q4W). No subjects were discontinued from the study
early because of AEs and there were no deaths. Two SAEs
were reported for AMG-403-treated subjects: gastrointes-
tinal perforation (10 mg SC Q4W) and knee arthroplasty
(20 mg SC Q4W). Neither SAE was considered by the
investigator to be treatment-related. Two patients with
knee OA in the 20-mg SC Q4W group experienced
CTCAE (common terminology criteria for adverse events)
grade 2 neurosensory AEs (moderate severity), which
triggered the activation of a protocol-specified stopping
rule for the entire dose group. As a result, three subjects
on 20 mg SC Q4W who were randomized to AMG 403
did not receive the fourth dose.
The common terminology criteria for adverse events
(i.e., mild, moderate, or severe) were used to characterize
AEs following AMG 403 or placebo. As noted in Table 2,
the pain-related AEs reported in the two studies were
headache, arthralgia, myalgia, pain in extremities, and
back pain. Of these AEs, 21 occurred in AMG 403-
treated subjects and 12 in placebo-treated subjects. All
pain-related AEs in AMG-403-treated subjects were
mild to moderate in severity. It should be noted that the
two pain-related AEs (arthralgia and myalgia) observed
in subjects with OA could be OA-related and therefore
confounding with respect to study drug use.
Immunogenicity
A total of 14 out of 52 AMG 403-treated subjects (27 %,
combined single- and multiple-dose studies) were
Table 1 Subject demographics and disease characteristics
Single ascending dosea Multiple ascending dosea
Demographics and disease characteristics IV SC SC Q4W × 4
Placebob 1 mg 3 mg 10 mg 30 mg 10 mg 30 mg Placebo 3 mg 10 mg 20 mg
(N = 12) (N = 6) (N = 6) (N = 5) (N = 6) (N = 5) (N = 6) (N = 6) (N = 6) (N = 6) (N = 6)
Age, years 25.2 35.0 30.2 22.8 46.7 31.6 28.2 54.7 53.0 48.7 52.7
(6.3) (12.0) (11.2) (2.8) (5.0) (9.2) (9.5) (9.7) (6.8) (8.7) (5.5)
Weight, kg 73.1 73.8 76.8 71.2 74.2 82.8 76.7 81.5 93.4 101 112
(91) (6.5) (7.8) (12.2) (10.0) (8.9) (10.7) (6.1) (18.1) (16.5) (10.3)
Male, % 92 100 100 100 83 100 100 17 67 50 50
Mean total WOMAC score nac na na na na na na 51.1 46.3 49.8 68.7
(9.3) (6.4) (8.1) (3.7)
Mean VAS score of patients’ disease assessments na na na na na na na 35.5 52.3 48.3 59.0
(8.3) (8.0) (6.6) (6.0)
Mean score of physician’s disease assessments na na na na na Na na 2.17 2.33 2.50 2.00
(0.48) (0.33) (0.22) (0.26)
All data are mean (SD), unless stated otherwise. aHealthy volunteers and patients with knee osteoarthritis were administered single- or multiple-doses of AMG 403,
respectively. bCombined intravenous (IV) and subcutaneous (SC) placebo subjects. cNot applicable for healthy volunteer subjects. Q4W once every four weeks,
WOMAC Western Ontario and McMaster Universities Osteoarthritis Index, VAS visual analog scale, na not applicable
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Table 2 Adverse events
Single ascending dosea Multiple ascending dosea
IV SC All SC Q4W × 4 All Total
Adverse events Placebo 1 mg 3 mg 10 mg 30 mg 10 mg 30 mg AMG 403 Placebo 3 mg 10 mg 20 mg AMG 403 AMG 403
(N = 12) (N = 6) (N = 6) (N = 5) (N = 6) (N = 5) (N = 6) (N = 34) (N = 6) (N = 6) (N = 6) (N = 6) (N = 18) (N = 52)
Serious adverse
events, n (%)b
0 0 0 1 0 0 0 1 0 0 1 1 2 3
(0) (0) (0) (20) (0) (0) (0) (3) (0) (0) (17) (17) (11) (6)
TEAEs reported
by ≥5 % of
subjects, n (%)c
8 3 1 5 4 3 6 22 6 6 6 6 18 40
(67) (50) (17) (100) (67) (60) (100) (64) (100) (100) (100) (100) (100) (77)
Headache 3 1 0 1 1 0 3 6 2 2 1 1 4 10
(25) (17) (0) (20) (17) (0) (50) (18) (33) (33) (17) (17) (22) (19)
Herpes simplex/
oral herpes
1 1 1 1 1 0 1 5 0 0 0 2 2 7
(8) (17) (17) (20) (17) (0) (17) (15) (0) (0) (0) (33) (11) (13)
Nasopharyngitis 2 1 0 0 1 1 2 5 0 0 1 1 2 7
(17) (17) (0) (0) (17) (20) (33) (15) (0) (0) (17) (17) (11) (13)
Arthralgia 0 0 0 0 0 0 0 0 3 2 1 1 4 4
(0) (0) (0) (0) (0) (0) (0) (0) (50) (33) (17) (17) (22) (8)
Dizziness 2 0 0 0 1 1 1 3 1 1 0 0 1 4
(17) (0) (0) (0) (17) (20) (17) (9) (17) (17) (0) (0) (6) (8)
Pain in extremity 0 0 0 0 1 0 3 4 0 0 0 0 0 4
(0) (0) (0) (0) (17) (0) (50) (12) (0) (0) (0) (0) (0) (8)
Paresthesia 1 0 0 0 1 0 0 1 0 0 0 3 3 4
(8) (0) (0) (0) (17) (0) (0) (3) (0) (0) (0) (50) (17) (8)
Hyperesthesia 0 0 0 0 0 0 3 3 0 0 0 0 0 3
(0) (0) (0) (0) (0) (0) (50) (9) (0) (0) (0) (0) (0) (6)
Joint effusion 0 0 0 0 0 0 0 0 0 0 1 2 3 3
(0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (17) (33) (17) (6)
Myalgia 1 0 0 0 1 0 0 1 1 2 0 0 2 3
(8) (0) (0) (0) (17) (0) (0) (3) (17) (33) (0) (0) (11) (6)
Nausea 0 0 0 0 0 0 0 0 0 2 0 1 3 3
(0) (0) (0) (0) (0) (0) (0) (0) (0) (33) (0) (17) (17) (6)
Pharyngolaryngeal
pain
2 1 0 0 1 1 0 3 0 0 0 0 0 3
(17) (17) (0) (0) (17) (20) (0) (9) (0) (0) (0) (0) (0) (6)
Osteoarthritis 0 0 0 0 0 0 0 0 0 2 1 0 3 3
(0) (0) (0) (0) (0) (0) (0) (0) (0) (33) (17) (0) (17) (6)
Upper respiratory
tract infection
0 0 0 0 0 0 0 0 4 2 1 0 3 3
(0) (0) (0) (0) (0) (0) (0) (0) (67) (33) (17) (0) (17) (6)
Fatigue 0 0 0 0 1 1 0 2 0 0 0 0 0 2
(0) (0) (0) (0) (17) (20) (0) (6) (0) (0) (0) (0) (0) (4)
Diarrhea 0 0 0 0 0 0 0 0 2 1 0 0 1 1
(0) (0) (0) (0) (0) (0) (0) (0) (33) (17) (0) (0) (6) (2)
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considered ADA positive because in at least one sample
there was positive binding of ADA to AMG 403 during
the treatment period. In the single- and multiple-dose
studies there were one (2.9 %) and 13 (72 %) of subjects
who were positive for ADA binding, respectively (30 mg
IV single dose (1/6 subjects); 3 mg SC Q4W (4/6), 10
mg SC Q4W (4/6), and 20 mg SC Q4W (5/6) multiple
dose). None of the ADA-binding-positive samples were
positive for neutralizing antibodies.
Pharmacokinetics
Mean serum AMG 403 concentration-time profiles after
single (healthy volunteer) and multiple (knee OA) doses
are shown in Fig. 1. Four of six healthy volunteers
administered a single 1-mg IV dose had serum concen-
trations below or near the LLOQ and were not included
in the analysis. After a single AMG 403 dose, max-
imum serum concentrations (Cmax) and area under
the concentration-time curve (AUC0-t) increased ap-
proximately dose-proportionally for IV (3 to 30 mg)
and SC (10 to 30 mg) administration. Elimination rates
were similar for all groups based on mean clearance
(CL 0.232 to 0.329 L/day) and half-life (19.6 to 25.8
days) values. Mean SC bioavailability (F) ranged from
77.0 % to 88.5 %.
Multiple SC doses (3, 10, or 20 mg Q4W) in patients
with knee OA resulted in approximately dose-proportional
mean Cmax and AUC0-t values, and median time to Cmax
was 7.5 to 9.0 days after the fourth dose. Elimination rates
(mean CL/F and half-life) were similar among the three SC
Q4W dose groups. AMG 403 concentrations after the
fourth dose appeared to achieve steady state and moderate
accumulation was observed compared with the first dose
(1.8-fold to 2.4-fold AUC0-t increase). Collectively, both
single- and multiple-dose studies indicate AMG 403
exhibits linear PK in the tested dose range.
Table 2 Adverse events (Continued)
Back pain 2 0 0 0 0 0 0 0 0 0 0 0 0 0
(17) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0)
Toothache 0 0 0 0 0 0 0 0 2 0 0 0 0 0
(0) (0) (0) (0) (0) (0) (0) (0) (33) (0) (0) (0) (0) (0)
aHealthy volunteers and patients with knee osteoarthritis were administered single- or multiple-doses of AMG 403, respectively. bNo serious adverse events were
considered to be treatment-related. cBased on placebo or AMG 403 groups combined, respectively, and ordered by event frequency for AMG 403. IV intravenous,
SC subcutaneous, TEAEs treatment-emergent adverse events
Fig. 1 AMG 403 concentration-time profiles following single and repeat dose administration. AMG 403 was administered intravenously (IV) or
subcutaneously (SC) and serum AMG 403 levels were measured pre-dose through end of study. Each point represents the mean (+SD) AMG
403 concentration. a Healthy volunteers received a single IV or SC dose of AMG 403 (1–30 mg, LLOQ= 0.0016 μg/mL). b Patients with knee osteoarthritis
received a once-monthly SC dose of AMG 403 (3–20 mg, LLOQ= 0.0051 μg/mL) for up to four dose administrations. Arrows represent dose administration
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Population pharmacokinetic modeling with exploratory
covariate analysis
The base pop PK model was established by fitting a two-
compartment model to the combined individual PK data
from the single- and multiple-dose studies. The pop PK
parameters (ka = 0.175 day
−1; CL = 0.254 L/day; Vc = 3.89
L; Vp = 2.92 L; Q = 0.784 L/day; F = 73.6 %) were esti-
mated with good precision (standard error ≤17 %). The
between-subject variability (BSV) for each parameter
was 31 % to 34 %, except for ka (82 %). One thousand
trial simulations were performed based on the pop PK
model to compare the predictions with the observed PK
in a visual predictive check (VPC, Fig. 2). The results
show that the majority of observed AMG 403 concentra-
tions are within the 80 % prediction interval, indicating
the observed AMG 403 PK profile and BSV are well-
characterized by the pop PK model.
Select covariates that commonly influence antibody CL
and Vc, such as body weight, disease status, and ADA,
were chosen for an exploratory analysis using the pop PK
model (Fig. 3). Body weight (across a range of 57.0 to
124.5 kg) as a continuous covariate on either CL or Vc did
not significantly improve the model fit. As a dichotomous
covariate on CL, disease status (diagnosis of knee OA) did
not affect CL nor improve the model fit. Binding ADA as
a dichotomous covariate did not significantly alter CL in
the pop PK model for the 14 ADA positive subjects (n = 1,
single dose; n = 13, multiple dose). Median CL for ADA
positive subjects compared to ADA negative subjects was
negligibly higher (12 %).
AMG 403 efficacy in patients with knee OA
Mean change from baseline for total WOMAC scores
showed an apparent dose-dependent improvement at
Fig. 2 Visual predictive check of the AMG 403 population pharmokinetics (PK) model. A two-compartment model was fit simultaneously to
individual AMG 403 PK data from healthy volunteers (HV) and patients with knee osteoarthritis (OA). The model parameter estimates were used to
simulate 1000 trials for a visual predictive check. The predicted median PK (solid line) and 80 % prediction interval (shaded area) are shown with
the observed individual concentrations (solid dot). Note the different x-axis scales for the single-dose and multiple-dose regimens. IV intravenous,
SC subcutaneous
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the first time point after the first dose in the AMG 403
treatment groups and was generally maintained through-
out the dosing period (Fig. 4). Marked and meaningful
improvement was observed in mean change from baseline
in VAS scores of patient disease assessment from the first
time point after the first dose and was generally main-
tained throughout the dosing period. These observations
were not as apparent in the placebo group. Additionally,
mean change from baseline for total WOMAC scores and
VAS scores for patient disease assessment showed sus-
tained clinical effect in the AMG-403-treated groups at
least 28 days after the final dose compared with the
placebo group. Treatment effects for the 20 mg SC Q4W
AMG 403 group trended towards baseline earlier than
others after day 98, possibly because three of the six sub-
jects in this group did not receive the fourth (final) dose
of AMG 403. Results from the physician disease assess-
ment showed a similar though less dramatic trend to the
total WOMAC and patient disease assessment (data not
shown).
Discussion
NGF is a secreted factor that controls the sensitivity of
primary sensory neurons and is thought to play a signifi-
cant role in nociception [11, 12]. Sequestration of NGF
in animal models and humans has provided compelling
evidence for the use of an anti-NGF therapy in produ-
cing pain relief for OA [11, 12, 14–19]. AMG 403 is a
fully human anti-NGF monoclonal antibody (IgG2)
undergoing clinical development for the treatment of
OA-related pain, and the current report presents safety,
tolerability, pharmacokinetics, immunogenicity, and effi-
cacy from two phase I studies with healthy volunteers
and patients with knee OA.
The combined single- and multiple-dose studies showed
AMG 403 was generally well-tolerated with an acceptable
safety profile in both healthy volunteers and patients with
knee OA. No clinically significant abnormalities in electro-
cardiograms, safety laboratory tests, or vital signs were
reported. The three SAEs were not considered treatment-
related. The neurosensory TEAEs were likely related to
AMG 403 sequestration of NGF. The CTCAE grade 2
neurosensory AEs experienced by two patients with knee
OA in the 20 mg SC Q4W group resolved over time, but
activated a protocol-specified cohort stopping rule that
prevented administration of the fourth AMG 403 dose to
three subjects. The majority of TEAEs did not appear to
be dose-dependent, however, paresthesia, pain in an
extremity, and hyperesthesia were only observed at the
highest dose level (30 mg AMG 403) for AMG-403-
treated subjects and showed reversibility. A phase II study
of AMG 403 (fulranumab) in patients with knee or hip
OA (n = 476) also reported paresthesia as a common
TEAE (7 %) in AMG-403-treated patients but a dose-
dependent effect was not observed [21]. A meta-analysis
of patients with knee or hip OA from 13 clinical trials of
the three anti-NGF antibody therapies (tanezumab, n = 10;
fasinumab, n = 1; AMG 403, n = 2) assessed the effects of
Fig. 3 Covariate effects on AMG 403 clearance (CL) and (Vc). Possible
covariate effects were explored for individual CL and Vc parameters
derived from simultaneous population pharmacokinetics modeling of
data from healthy volunteers (HV) and patients with knee osteoarthritis
(OA). Effect of body weight on CL (a) and Vc (b) is illustrated with a
loess regression line. c The effect of anti-drug antibody (ADA) status
(negative (n = 34) or positive (n = 14)) or disease status (HV (n = 30) or
patients with knee OA (n = 18)) on CL is presented in box plots (median,
25th, and 75th percentiles; whiskers are 1.5 times the inner-quartile
range and dots are outliers)
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Fig. 4 Clinical effect of AMG 403 in patients with knee osteoarthritis. Mean change (+ standard error) from baseline values over time for each dose group
were plotted for total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (a) score and visual analog score (VAS) (b) for patient
disease assessment. Arrows represent subcutaneous dose administrations (SC)
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potentially dose-limiting AEs from anti-NGF treatment
based on a patient’s ability to remain on study. It was
reported that higher anti-NGF antibody doses had a
higher odds ratio for the rate of subject withdrawal due to
AEs compared with placebo [22]. In the same analysis,
however, lower doses were comparable with placebo for
rate of subject withdrawal.
AMG 403 immunogenicity was limited to ADA-positive
responses in binding assays that were all negative for neu-
tralizing antibodies. The greater ADA incidence in the
multiple-dose study (72 %, patients with knee OA) com-
pared with the single-dose study (2.8 %, healthy volun-
teers) will need further investigation. A lower ADA
incidence (<2 %) was observed in phase II studies with
AMG 403 using revised immunogenicity assay method-
ology to reduce the potential for false-positive ADA
caused by NGF dimer interference [23]. It is possible the
immunogenicity assay methodology for the current stud-
ies could have yielded greater false-positive ADA results.
AMG 403 PK was linear and approximately dose-
proportional, and SC administration showed substantial
bioavailability. Integration of the single- and multiple-dose
PK data into a pop PK model established a predictive
simulation tool that effectively recapitulated the observed
data and provided a foundation for integrating subsequent
clinical PK data for identifying novel dose levels and/or
regimens. Additionally, the pop PK model enabled an
exploratory covariate analysis to quantify the effects of
mechanistically plausible covariates (body weight, ADA,
and disease status) on CL and/or Vc. While it is common
for bodyweight to influence the CL or Vc of monoclonal
antibodies [24], it was not found to be a covariate for
AMG 403. It is possible a larger population with a greater
range of body weight is needed to better characterize the
impact of body weight on AMG 403 PK. ADA did not
appear to alter the elimination of AMG 403 since ADA
was not a covariate on CL in the current analysis. Finally,
NGF levels were not measured in healthy volunteers and
patients with knee OA; however, disease status was not a
PK covariate on CL suggesting OA-dependent effects on
NGF levels [14, 15] are not expected to significantly alter
AMG 403 PK.
Patients with knee OA treated with AMG 403 showed
signs of clinical benefit compared with placebo-treated
subjects after multiple doses. Mean total WOMAC
scores decreased from baseline values at the first time
point (study day 15) to beyond the fourth and final dose
(study day 98) in an apparent dose-dependent manner.
Additionally, patients’ disease assessments decreased
markedly from baseline during the same period. Clinical
effect based on physician disease assessment was less
striking but generally showed a trend for improvement
compared with placebo. Although variability of the effi-
cacy data was notable and the study was not powered to
evaluate the statistical significance of the efficacy mea-
sures, reported and observed pain-related treatment
effects seemed apparent for AMG 403 with sustained
response beyond the final dose. An adequately powered,
subsequent phase II study with AMG 403 established
clinically significant efficacy compared with placebo
using similar pain measures to those used in the current
report [21].
Conclusions
Blockade of NGF is a recent therapeutic paradigm for
treating chronic pain due to OA and may provide an im-
proved alternative for OA patients or possibly patients
with chronic neuropathic pain due to other diseases.
These phase I studies showed AMG 403, a human anti-
NGF monoclonal antibody, was generally safe, well-
tolerated, and exhibited linear, dose-proportional PK.
Intrinsic factors such as body weight, ADA, or disease sta-
tus did not appear to influence AMG 403 PK, but future
study will refine these characterizations. Initial clinical effi-
cacy results support the ongoing development of AMG 403
(now fulranumab) for the treatment of knee and hip OA.
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